Back

Elexacaftor/tezacaftor/ivacaftor (Trikafta(R)) does not affect the growth of Aspergillus fumigatus in vitro

BIQUAND, E.; KHAU, S.; FOUQUENET, D.; COSTES, F.; Chesnay, A.; Desoubeaux, G.; BRIARD, B.

2024-08-16 microbiology
10.1101/2024.08.12.607675 bioRxiv
Show abstract

Fungal infection, especially allergic bronchopulmonary aspergillosis, is a leading cause of infection-associated morbidity and death in patients with cystic fibrosis. We have previously discovered that the new leading therapeutic treatment in cystic fibrosis, CFTR modulators Elexakaftor/Tezacaftor/Ivacaftor (ETI, Trikafta(R)), drastically reduces the colonization and infection by Aspergillus fumigatus. However, the reasons for this decrease in patients are not known so far. In this study we have shown, using A. fumigatus reference strains and strains isolated from patients with cystic fibrosis, that CFTR modulators have no discernable impact on fungal growth in vitro. These results are consistent regardless of drugs concentration, demonstrating that treatment does not exert a direct antimicrobial or stimulatory effect in vitro on A. fumigatus conidia growth, when exposed to actual in vivo CFTR modulators concentration.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.